Abstract：Objective: To evaluate the efficacy and safety of budesonide combined with interferon α2b nebulization in the treatment of infantile bronchopneumonia. Methods: A total of 102 infants and young children with bronchopneumonia admitted to our hospital from 2021.09 to 2023.07 were enrolled. According to the random number table method, they were divided into the conventional group (conventional symptomatic treatment + budesonide atomization inhalation) and combined group (combined with interferon α2b atomization inhalation on the basis of the conventional group), with 51 cases in each group. The clinical efficacy, improvement time of symptoms (cough, wheezing, wheezing rale, three concave signs), blood gas indexes [oxygenation index, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2)], T lymphocyte indicators (CD3+CD4+, CD3+CD8+, CD3-CD19+) and peripheral blood inflammation indexes [Interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), C-reactive protein (CRP)] before and after treatment were compared between the two groups, and the adverse drug reactions were compared. Results: The total effective rate of the combined group (98.40%) was higher than that of the conventional group (86.27%) ((P<0.05). The improvement time of symptoms in the combined group was shorter than that in the conventional group (P<0.05). Before treatment, there were no statistical differences in serum indexes between groups (P>0.05). After treatment, the oxygenation index and PaO2 in the two groups were increased (P<0.05) while the PaCO2 was decreased (P<0.05), and the differences before and after treatment in the combined group were higher (P<0.05). No statistical differences were shown in T lymphocyte indexes between groups before treatment (P>0.05). After treatment, CD3+CD4+and CD3+CD8+ in both groups of children were risen (P<0.05) while CD3-CD19++ was declined (P<0.05), and the differences before and after treatment were higher in the combined group than those in the conventional group (P<0.05). Before treatment, there were no statistical differences in peripheral blood inflammation indexes between groups (P>0.05). After treatment, the peripheral blood inflammatory indexes (IL-6, TNF-α, CRP) in the two groups were significantly decreased (P<0.05), and the differences before and after treatment in the combined group were higher than those in the conventional group (P<0.05). There was no statistical significance in the total incidence rate of adverse drug reactions between the combined group (7.84%) and the conventional group (5.88%) (P>0.05). Conclusion: Budesonide combined with interferon α2 b atomization inhalation is beneficial to improve the clinical symptoms, lung function and immune inflammatory response of infants and young children with bronchopneumonia, and improve the efficacy, with high safety.
袁斌, 蔡金标, 王娟, 吕亚莉, 李晓会. 布地奈德联合干扰素α2b雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估[J]. 河北医学, 2024, 30(10): 1739-1744.
YUAN Bin, CAI Jinbiao, WANG Juan, et al. Evaluation of the Efficacy and Safety of Budesonide Combined with Interferon α2b Nebulization in the Treatment of Infantile Bronchopneumonia. HeBei Med, 2024, 30(10): 1739-1744.
[1] Chen LJ,Li JM,Zhang WD,et al.LncRNA NEAT1 activates MyD88/NF-κB pathway in bronchopneumonia through targeting miR-155-5p[J].Autoimmunity,2021,54(2):104-113. [2] Li B,Liu X.Clinical implications of Golgi protein 73 and granulocyte colony-stimulating factor and their related factors in children with bronchopneumonia[J].Pediatr (Rio J),2023,99(1):65-71. [3] Han X,Yang Y,Zhu Q,et al.Clinical value of atomization therapy in children with bronchopneumonia[J].Minerva Pediatr (Torino),2022,74(1):94-96. [4] 常秀,赵静,侯召权,等.基于TLR3/TRIF通路分析重组人干扰素α2b联合炎琥宁对病毒性肺炎患儿的疗效与作用机制[J].临床误诊误治,2023,36(2):128-132,152. [5] He C,Song C,Li M,et al.Meta-analysis of the effect and safety of recombinant human interferon α-2b combined with Baofukang suppository in the treatment of HPV infection[J].Am Transl Res,2022,14(11):7632-7642. [6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.急性气管-支气管炎基层诊疗指南(2018年)[J].中华全科医师杂志,2019,18(4):314-317. [7] Geng L,Tang X,Hua L,et al.The analysis of risk factors for recurrent wheezing in infants and clinical intervention[J].Transl Pediatr,2023,12(10):1810-1822. [8] Yang Z,Li C,Wang C,et al.Assessing the impact of meteorological conditions on outpatient visits for childhood respiratory diseases in urumqi,China[J].Occup Environ Med,2022,64(10):598-605. [9] Xiong R,Fu R,Wu Y,et al.Long-term infection and pathogenesis in a novel mouse model of human respiratory syncytial virus[J].Viruses,2022,14(8):1740-1753. [10] 陈佳怡,张晗,尚云晓.肺炎支原体肺炎支气管肺泡灌洗液中23SrRNA耐药基因阳性患儿的临床及支气管镜下特点[J].中华实用儿科临床杂志,2022,37(12):897-902. [11] 徐双云,汪佩林,房红娟.乙酰半胱氨酸辅助治疗肺炎支原体感染的效果及对TARC和IL-6及免疫球蛋白的作用[J].热带医学杂志,2023,23(2):237-240. [12] 吴建刚,陈玉梅,陈美元,等.哮喘患儿呼吸道病毒感染特征及其与α-干扰素治疗前后Th1、Th2细胞因子平衡的相关性研究[J].中国免疫学杂志,2021,37(15):1877-1882. [13] Gebre M,Uddin MF,Duke T,et al.Perception and experience of clinicians and caregivers in treating childhood severe pneumonia and hypoxemia using bubble continuous positive airway pressure in Ethiopian tertiary and general hospitals[J].PLoS One,2022,17(10):1-18. [14] Liu Y,Xie YZ,Shi YH,et al.Airway acidification impaired host defense against pseudomonas aeruginosa infection by promoting type 1 interferon β response[J].Emerg Microbes Infect,2022,11(1):2132-2146. [15] 麦朗君,翟佳羽,林烈桔,等.呼吸道合胞病毒下呼吸道感染患儿外周血miR-145表达及与Th1/Th2平衡的关系[J].河北医学,2020,26(8):1277-1281. [16] Yadav KK,Awasthi S.Childhood pneumonia: what's unchanged,and what's new[J].Indian Pediatr,2023,90(7):693-699.
2024, Vol. 30 
冀公网安备13080202000677号